Suzhou Alphamab Co., Ltd.
Clinical trials sponsored by Suzhou Alphamab Co., Ltd., explained in plain language.
-
New injection aims to stop dangerous bleeds in Tough-to-Treat hemophilia
Disease control OngoingThis study is testing whether regular injections of an experimental drug called KN057 can safely prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors. Participants are randomly assigned to receive either KN057 injections for a year or start wit…
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New injection could transform life for hemophilia patients by preventing dangerous bleeds
Disease control OngoingThis study is testing whether a new injection called KN057 can safely prevent bleeding episodes in people with hemophilia A or B. The trial involves 125 male participants aged 12-70 who currently experience frequent bleeds. Researchers will compare how often bleeds occur with KN0…
Phase: PHASE3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial aims to stop deadly clots after knee surgery
Prevention OngoingThis study is testing whether a new drug called KN060 works better than the standard medication (enoxaparin) at preventing dangerous blood clots in people having total knee replacement surgery. Researchers are comparing different doses of KN060 in 241 patients to see how well it …
Phase: PHASE2 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Prevention
Last updated Feb 27, 2026 15:19 UTC